Faculty of Medicine, Histology and Embryology, Atlas University, 34408 İstanbul, Turkey.
Photonics Center, Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA.
Biosensors (Basel). 2024 Jun 24;14(7):315. doi: 10.3390/bios14070315.
Wet Age-related macular degeneration (AMD) is the leading cause of vision loss in industrialized nations, often resulting in blindness. Biologics, therapeutic agents derived from biological sources, have been effective in AMD, albeit at a high cost. Due to the high cost of AMD treatment, it is critical to determine the binding affinity of biologics to ensure their efficacy and make quantitative comparisons between different drugs. This study evaluates the in vitro VEGF binding affinity of two drugs used for treating wet AMD, monoclonal antibody-based bevacizumab and fusion protein-based aflibercept, performing quantitative binding measurements on an Interferometric Reflectance Imaging Sensor (IRIS) system. Both biologics can inhibit Vascular Endothelial Growth Factor (VEGF). For comparison, the therapeutic molecules were immobilized on to the same support in a microarray format, and their real-time binding interactions with recombinant human VEGF (rhVEGF) were measured using an IRIS. The results indicated that aflibercept exhibited a higher binding affinity to VEGF than bevacizumab, consistent with previous studies using ELISA and SPR. The IRIS system's innovative and cost-effective features, such as silicon-based semiconductor chips for enhanced signal detection and multiplexed analysis capability, offer new prospects in sensor technologies. These attributes make IRISs a promising tool for future applications in the development of therapeutic agents, specifically biologics.
湿性年龄相关性黄斑变性（AMD）是工业化国家导致视力丧失的主要原因，常导致失明。生物制剂，即源自生物来源的治疗剂，在 AMD 中非常有效，尽管成本很高。由于 AMD 治疗费用高昂，因此确定生物制剂的结合亲和力至关重要，以确保其疗效，并对不同药物进行定量比较。本研究使用干涉反射成像传感器（IRIS）系统评估了两种用于治疗湿性 AMD 的药物的 VEGF 结合亲和力，这两种药物分别为基于单克隆抗体的贝伐单抗和基于融合蛋白的阿柏西普。两种生物制剂都可以抑制血管内皮生长因子（VEGF）。为了进行比较，将治疗分子以微阵列的形式固定在相同的载体上，并使用 IRIS 测量它们与重组人 VEGF（rhVEGF）的实时结合相互作用。结果表明，阿柏西普与 VEGF 的结合亲和力高于贝伐单抗，这与使用 ELISA 和 SPR 的先前研究结果一致。IRIS 系统的创新和具有成本效益的特点，例如用于增强信号检测的硅基半导体芯片和多路复用分析能力，为传感器技术提供了新的前景。这些特性使 IRIS 成为未来治疗剂，特别是生物制剂开发的有前途的工具。
